<DOC>
	<DOCNO>NCT00513474</DOCNO>
	<brief_summary>RATIONALE : Rasburicase may effective treatment graft-versus-host disease cause donor stem cell transplant . PURPOSE : This clinical trial study well rasburicase work prevent graft-versus-host disease patient hematologic cancer disease undergo donor stem cell transplant .</brief_summary>
	<brief_title>Rasburicase Preventing Graft-Versus-Host Disease Patients With Hematologic Cancer Other Disease Undergoing Donor Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate incidence severity acute graft-vs-host disease ( GVHD ) rasburicase-treated patient undergo myeloablative HLA-matched related unrelated donor allogeneic peripheral blood hematopoietic stem cell transplantation ( SCT ) hematologic malignancy compare outcomes historical control . Secondary - To evaluate efficacy ( term reduction uric acid level ) safety rasburicase patient undergo myeloablative allogeneic SCT . - To evaluate graft-versus-host host-versus-graft immune response rasburicase-treated patient . OUTLINE : This multicenter study . Patients receive conventional myeloablative conditioning regimen consist high dos cyclophosphamide , busulfan , etoposide , without total-body irradiation . Depending preparative regimen select , condition recipient take total 6 7 day . On day 0 , patient receive filgrastim ( G-CSF ) -mobilized HLA-matched , relate , unrelated donor allogeneic peripheral blood stem cell ( unmanipulated ) . Patients receive standard graft-vs-host disease prophylaxis consist cyclosporine tacrolimus methotrexate sirolimus . Patients receive rasburicase IV 30 minute , begin first day condition therapy , 5 consecutive day . If 5 day rasburicase patient 's uric acid plasma level remain 5 mg/dL , rasburicase may continue 7 day total . Blood obtain day 0 14 , 28 , 42 day post-transplant immunologic study , include quantitative analysis follow recovery T cell , B cell , natural killer cell , dendritic cell ( DC ) , monocytes use flow cytometry ( FCM ) ; phenotypic analysis T cell , DC monocytes FCM ; lymphocyte activation analysis : CD3 , CD4 , CD8 , CD25 2 . CD3 , CD8 , CD71 , CD69 ; DC analysis : CD45 , CD14 , DR , CD86 , CD80 2 . CD45 , CD14 , CD40 , CD11c ; vitro functional study mix lymphocyte reaction ( MLR ) cell-mediated lysis ( CML ) ass graft-versus-host host-versus-graft response . Peripheral blood collect chimerism study day 28 100 post-transplant . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients hematologic malignancy conventional myeloablative allogeneic stem cell transplantation deem clinically appropriate eligible conventional myeloablative allogeneic stem cell transplantation treatment plans/protocols , include follow : NonHodgkin lymphoma Hodgkin lymphoma ( relapsed refractory disease ) Chronic lymphocytic leukemia ( receive one previous treatment regimen ) Acute myelogenous lymphoblastic leukemia ( AML/ALL ) ( highrisk disease , first complete remission [ CR1 ] subsequent remission , primary refractory disease ) Chronic myelogenous leukemia tyrosinekinase resistant chronic phase , accelerate blast phase , primary refractory disease Myelodysplastic syndromes IPSS ( International Prognostic Scoring System ) highintermediate highrisk group Other hematologic disorder allogeneic stem cell transplantation appropriate ( e.g. , myelofibrosis ) Patients relapse standard autologous and/or allogeneic bone marrow transplant eligible Must receive filgrastim ( GCSF ) mobilize related unrelated donor allogeneic peripheral blood stem cell Patients receive hematopoietic stem cell source marrow graft umbilical cord blood eligible study Donor must HLAgenotypically phenotypically 6 6 antigen match ( A , B , DR locus ) relate unrelated PATIENT CHARACTERISTICS : Inclusion criterion : Patients `` currently active '' second malignancy nonmelanoma skin cancer register survival second malignancy expect 1 year Ejection fraction ≥ 45 % either radioisotope MUGA scan ECHO Lung DLCO ≥ 50 % predict symptomatic pulmonary disease Mini Mental Status Exam Score ≥ 20 Patients must expect life expectancy least 3 month Patients symptomatic visceral , blood stream nervous system opportunistic infection eligible infection appropriately treat controlled Patients fungal infection must treatment least one month must proof regression infection prior enrollment Patients may antibiotics time transplant Exclusion criterion : HIV infection Uncontrolled diabetes mellitus Active congestive heart failure cause Previous history congestive heart failure allow Active angina pectoris Oxygendependent obstructive pulmonary disease Failure demonstrate adequate compliance medical therapy followup Known history G6PD deficiency history hemolysis indicative G6PD deficiency PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>